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evaluation of canagliflozin 300mg versus sitagliptin 100mg in patients inadequately 
controlled on MET+SU. Methods: Two 40-year simulations were performed using a 
validated economic model (ECHO-T2DM), differing only in the hypoglycemia disutility 
weights: (A) CADTH and (B) new estimates. Disutilities for T2DM-related complica-
tions and other adverse events were sourced from the literature. Data for patient 
characteristics, treatment effects (i.e. A1C, SBP, BMI, and cholesterol), and rates of 
adverse events were obtained from a previously reported 52-week trial, where canagli-
flozin 300mg demonstrated statistically superior A1C-lowering, as well as reductions 
in blood pressure and weight versus sitagliptin 100mg. Hypoglycemic event rates 
were similar. In the simulations, insulin (which has an excess risk of hypoglycemia) 
was added and titrated as necessary to maintain A1C < 7.0%. Results: Discounted 
QALYs for canagliflozin and sitagliptin were (A) 8.4 and 8.32; (B) 7.91 and 7.81. The 
higher QALYs associated with canagliflozin versus sitagliptin are largely attributable 
to the delay in the need for insulin for canagliflozin-treated patients. The contribu-
tion of hypoglycemic events to these total QALY differences was greater in scenario 
B (20.8%) than scenario A (2.3%). ConClusions: These results illustrate the need to 
carefully consider downstream assumptions in economic evaluations. Using the older 
values yielded 20% fewer net QALYs, implying that the corresponding ICER would be 
approximately 25% greater.
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objeCtives: Risk of the outcome is a mathematical determinant of the absolute 
treatment benefit of an intervention. While substantial risk heterogeneity can lead 
to clinically important differences in treatment effect, the degree to which risk varies 
within randomized clinical trials (RCTs) is largely unknown. Methods: We selected 
all RCTs that had greater than ~1000 enrollees and clinical outcomes from several 
sources (NHLBI, NIDDK, Trials journal). We derived Cox or logistic regression models 
using established risk factors blinded to treatment assignment. Risk heterogene-
ity was evaluated using the extreme quartile risk ratio (EQRR, the ratio of outcome 
rates in the lowest risk quartile to that in the highest). Skewness was evaluated with 
median to mean risk ratio (MMRR, the ratio of risk in the median risk patient to the 
average). Results: We describe the distributions of 34 unique risk analyses from 25 
heterogeneous large trials. Overall event rates across studies ranged from 3% to 63% 
(median= 15%, interquartile range [IQR] 10% to 23%). The number of established risk 
factors included in each risk model ranged from 4 to 32 (median= 9, IQR 7 to 11); events 
per variable ranged from 13 to 1515 (median= 46, IQR 32 to 66). Models had estimated 
C-statistics of 0.58 to 0.81 (median 0.69, IQR 0.65 to 0.73). EQRR ranged from 1.8 to 21.6 
(median= 4.1, IQR 3.0 to 5.5). The MMRR ranged from 0.5 to 1.0 (median= 0.87, IQR 0.80 
to 0.89). The model C-statistic and the outcome rate of the trial determined the EQRR 
(r-squared= 0.87) and the MMRR (r-square= 0.81). ConClusions: Clinically significant 
risk heterogeneity is common even in phase 3 “efficacy” trials. The typical patient is 
generally at lower risk than reflected by the trial summary results. A risk stratified 
approach to trial analysis is feasible and may be most clinically informative where 
the outcome is predictable and uncommon.
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objeCtives: To present an efficient new methodology to calculate cost and effects 
of alternative interventions for Diabetes Mellitus (DM), and to validate this approach 
by comparing cost-effectiveness results when identical interventions for DM are 
simulated by this Markov model (DELTA) or by a well-known Micro-Markov model 
(CARDIFF). Methods: The Markov model (DELTA) deals with multiple competing 
events; complications are modeled as individual Markov chains. By creating a dynamic 
link between the life table and the subdiseases, any change in the individual Markov 
chains is propagated throughout the entire model. Advantage of this approach is a 
considerable decrease in computational time. In order to test the validity of the DELTA 
model and its applicability in modeling interventions and treatment sequences in 
T2DM, cost-effectiveness results were compared with published outcomes predicted 
by the CARDIFF model. Similar treatment sequences were applied as well as identical 
key data sources for predicting the occurrence of diabetes related events (equations 
UKPDS Outcomes model), quality of life effects attached to BMI changes and hypo-
glycemia, and inputs related to drug- and health care costs. Results: Incremental 
life-years gained (LYG), discounted incremental costs, incremental QALYs and ICUR 
in the Cardiff and DELTA models are 0.050 LYG, £1,246, 0.467 QALY, £2,671/QALY, and 
0.031 LYG, £1,021, 0.555 QALY, £1,841/QALY, respectively. Differences between model 
outcomes may be explained by the underlying independency assumptions of the 
DELTA model. ConClusions: The point estimates obtained by both models using 
similar scenarios seem to resonate quite well. However, further research is needed 
to substantiate the observed differences in outcomes. Additional insight can be pro-
vided by comparing the confidence intervals around the estimates, which will be 
incorporated shortly. It seems the DELTA approach offers a flexible way to model 
multiple diseases simultaneously. The loss of subtlety and necessary assumptions 
may outweigh the gains in clarity and computational speed.
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ing will drive up the quality and efficiency of pharmacoepidemiological database 
studies.
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objeCtives: Using observational databases to calculate vaccination rate is challeng-
ing because of limited continuous enrollment and loss to follow-up. The objective of 
this study was to apply the concept of survival analysis in estimating rate of pneumo-
coccal vaccination among adults with the high-risk medical conditions included in the 
ACIP (Advisory Committee on Immunization Practices) recommendations. Methods: 
This was a retrospective cohort study using a large administrative claims database. 
The study cohort was 19-64 years old adults with newly diagnosed high-risk condi-
tions (HIV/AIDS, diabetes, asplenia, chronic lung disease, chronic renal disease, chronic 
heart disease, organ transplant, cochlear implant, cancer, chronic liver disease and 
alcoholism) during 2007 to 2010 and had at least three years of continuous enrollment. 
Subjects were followed from the initial diagnosis date to the end of enrollment or 
2011. Cox proportional hazard model was used to analyze the association of high-
risk medical conditions with pneumococcal vaccination after controlling potential 
confounders. Survival curves were estimated from the Cox model. Results: A total of 
946,898 eligible subjects were followed for a total of 2,358,563 person-years, of which, 
71,298 subjects received pneumococcal vaccine. The overall pneumococcal vaccination 
rate was 3.023/100 person years (95%CI= 3.001, 3.045). Pneumococcal vaccination rate 
was the highest in HIV/AIDS patients (16.499/100 person years, 95%CI= (15.374,17.683)) 
followed by diabetes patients (4.520/100 person years, 95%CI= (4.466,4.574)) and was 
the lowest in alcoholism patients (1.042/100 person years, 95%CI= (0.953,1.137)). After 
controlling potential confounders, high-risk conditions had a significant association 
with pneumococcal vaccination. Compared to patients with alcoholism, HIV/AIDS 
patients were 11 times more likely to receive pneumococcal vaccination (HR= 11.964, 
95%CI= (10.696,13.382), p< 0.0001). ConClusions: Pneumococcal vaccination rate 
was more accurately analyzed by applying survival analysis because a larger and 
more representative sample was constructed and loss to follow-up was taken into 
account. Study suggests pneumococcal vaccination rate was low in adults with newly 
diagnosed high-risk conditions.
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objeCtives: Open data sharing for large-scale studies is an expensive and resource-
wasteful approach that does not scale well with participating sites. Critically, some 
data simply cannot be shared due to privacy concerns and/or risk of re-identifica-
tion. We pursue distributed computation that only shares data derivatives, such as 
statistical summaries, as a notable alternative allowing data holders to maintain 
control over data access. Privacy protection, if implemented via the differential privacy 
framework, can quantify and controllably reduce the risk of sharing the results of 
computations on private data. Unfortunately, it can impair the quality of statistical 
estimates at a single site. Using structural MRI data we present a distributed differ-
entially private classifier that greatly improves the accuracy. Methods: We used a 
combined MRI dataset from four separate schizophrenia studies conducted at Johns 
Hopkins University (JHU), the Maryland Psychiatric Research Center (MPRC), the 
Institute of Psychiatry, London, UK (IOP), and the Western Psychiatric Institute and 
Clinic at the University of Pittsburgh (WPIC). The sample comprised 198 schizophre-
nia patients and 191 matched healthy controls. We trained differentially private clas-
sifiers on these data using a method that minimizes a perturbed version of the SVM 
classifier. The outputs of these classifiers were used to train a logistic regression 
classifier. A combined SMVs plus logistic regression classifier was tested for accu-
racy. Results: Using 100 random splits of data into 70% training and 30% validation 
groups followed by splitting the training set into 11 sites of 24/25 subjects each, we 
assessed classification accuracy at each site and of combination per split. Average 
site-accuracy was below 78%, while our combined classifier averaged to 96%: sub-
stantial and significant improvement with Bonferroni-corrected p-values below 
1.8e-33. ConClusions: Our approach provides a way to enable use of distributed 
big data while still providing privacy and thus a much larger effective sample size.
ReseaRch on Methods – Modeling Methods
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objeCtives: Differences in the frequency and severity of hypoglycemic episodes 
associated with alternative treatments often contribute significantly to differences 
in QALYs (the denominator of the cost-effectiveness ratio). The 2013 T2DM CADTH 
report examining third-line therapy used disutility values from studies conducted 
before 2009 based on small samples. A new study with over 1,600 individuals with 
T2DM (including Canadian respondents) found disutility estimates that were mean-
ingfully greater (e.g. 0.005 versus 0.000004767 per non-severe hypoglycemic event). 
This analysis examined the impact of these alternative estimates on QALYs in an 
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objeCtives: The objective was to determine the most effective logistic regres-
sion models in terms of explaining the greatest amount of variance regarding four 
outcomes: graft versus host disease (GVHD), liver toxicity, neurotoxicity, and mor-
tality, among a cohort of patients undergoing hematopoietic stem cell transplanta-
tion. Methods: Busulfan is used in combination with fludarabine or clofarabine 
as part of an effective chemotherapy based myeloablative preparative regimen for 
patients undergoing stem cell transplantation. Pharmacokinetic data regarding 
patient busulfan clearance was used in the analysis, since dosing is very sensi-
tive. Other clinically relevant covariates included: age, gender, race, primary can-
cer diagnosis, type of transplant (autologous or allogeneic), and prior transplant 
history. Descriptive statistics and logistic regression analyses were performed to 
assess the effect of these variables on each of four outcomes: GVHD, liver toxic-
ity, neurotoxicity, and mortality. Hosmer and Lemeshow goodness-of-fit tests and 
c-statistics were used to optimize the models. Only aggregate level information 
was reported. Statistical significance was set at 0.05. Results: Data on a cohort of 
752 patients undergoing hematopoietic stem cell transplantation were collected. 
Most patients were: 46.7±15.8 years old, male (59.8%), Caucasian (68.6%), with acute 
myeloid leukemia (28.9%), underwent an allogeneic transplant (67.0%), and had not 
received a prior transplant (93.5%). Controlling for the covariates listed, the mod-
els resulted in Hosmer and Lemeshow goodness-of-fit test statistics (chi-square, 
number of degrees of freedom, p-value) for each dependent variable as follows: GVHD 
(2.57, 5, 0.77); liver toxicity (5.17, 8, 0.74); neurotoxicity (8.45, 8, 0.39); and mortality 
(5.95, 8, 0.65). The c-statistics for each model were: GVHD (0.87); liver toxicity (0.74); 
neurotoxicity (0.75); and mortality (0.72). ConClusions: The logistic regression 
models used were effective in determining the outcomes of GVHD, liver toxicity, 
neurotoxicity, and mortality, among a cohort of patients undergoing hematopoietic 
stem cell transplantation.
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objeCtives: Vaccination coverage rate is usually obtained from the decision of 
an immunization policy. Actual impacts to the outcomes by different vaccinated 
recipients selection and their coverage rates were seldom discussed. This study 
aims to use a transmission dynamic model (TDM) based on a system of differen-
tial equations in susceptible-infectious-recovered model to optimally explore the 
estimates of coverage rates. Methods: 23-valent pneumococcal polysaccharide 
vaccines (PPV23) and 13-valent pneumococcal conjugate vaccines (PCV13) have been 
shown their cost-effectiveness in elderly and children, respectively. Scenarios of 
PPV23 to the elderly aged 65+ years and PCV13 to children aged below 4 years were 
assumed and TDM was used. All epidemiological parameters were obtained from the 
Taiwan’s National Health Insurance Database and the vaccine efficacy was obtained 
from the literatures. Various vaccination coverage rates were considered. The equa-
tions were solved using the fourth-order Runge–Kutta method implemented in R 
Statistical Software. Results: The estimates of PPV23 for the elderly and PCV13 
for the children were both 70% to achieve optimal goal. Increasing the rate over 
70% will not significantly decrease the total number of pneumonia infection and 
death but increase the costs. ConClusions: This study proposed an approach 
to estimate the optimal vaccination coverage rate based on the TDM simulations. 
This will provide value-based information of vaccination policy in the decision of 
vaccine quantity and recipients.
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objeCtives: The objective of this paper is the analysis of practice or 
physicians’attributes in addition to patient or products ‘attributes to explain pat-
terns of drug utilization in predictive disease models including reversed conjoint 
data. In previous European physicians’cost sensitivity studies, physicians’ charac-
teristics such as demographics, solo/group practices, types of remuneration, location 
(depressed/wealthy areas) were not conclusive (ENDEP/biomed, 2003). This analysis 
explores additional physicians’attributes more related to professional activities 
(Rischatsch Zweifel,2012) such as referrals or restrictions to specialists, quality obli-
gations and incident reporting. Methods: Different types of physicians’ choice 
sets are designed with sets of attributes classified in subgroups Z1,Z2,Z3 ( Z1 for 
products, Z2 for patients, Z3 for physicians’ attributes) . A sample of 688 patients 
diagnosed with diabetes type II without complications (ICD 250.00) is extracted 
from the National Medical Care Survey (Huttin/Wong, 2010). Practices are grouped 
by stages of IT computerization for billing and EMRs. Pharmacological treatment 
(including oral, injectables and supplies) is defined with a drug list from Facts and 
Comparisons over three successive years (e.g. 2004/2005/2006) for a 2005 database. 
Physicians’treatment choices are analyzed with a disease model integrating Z3 
physicians’attributes on subsets of physicians. The cumulative logistic model is 
run with SAS. Results: Results of the predictive disease model on diabetes type 
II show on the 2005 analytical dataset that drug utilization is much lower when 
physicians in clinical practice use a referral process (0.46). The stage of computeri-
zation of practices especially with ebilling remains highly significant (lower drug 
utilization when ebilling is used (0.69)). Additional runs are tested with predictive 
models on other chronic conditions (Asthma and Hypertension). ConClusions: 
objeCtives: CDC guidelines recommend hepatitis C virus (HCV) screening for 
the 1945-1965 birth cohorts. Since HCV prevalence is decreasing with birth-year, 
age-specific screening is less cost-effective in later cohorts. To inform the optimal 
time to discontinue screening, collecting additional information may be valu-
able, though when this information should be collected is unclear. Methods: 
We apply a Markov decision process framework to evaluate how long to continue 
HCV screening in US men. We identify the optimal information collection policy 
for two parameters assumed constant across cohorts - reductions in quality-of-
life from awareness of HCV-positive status and the fibrosis-stage distribution at 
screen-detected diagnosis at age 50 - alone and in combination with information 
collection about HCV prevalence which is decreasing across cohorts. We estimate 
lifetime costs and benefits using a previously-developed HCV screening model and 
HCV prevalence dynamics derived from NHANES. The assumed willingness-to-
pay threshold is $75,000 per QALY. Results: The presence of a parameter which 
varies across cohorts influences the per-person value-of-information about both 
time-varying and static parameters. In these cases, we show analytically that it 
may be optimal to delay information collection. Given our prior beliefs, the optimal 
strategy is to collect sample information about the reduction in quality-of-life 
from awareness of HCV-positive status immediately and then, depending on the 
result of that study, collect information on HCV prevalence 3 to 20 years in the 
future. This strategy increases the expected incremental net monetary benefit by 
$2.3 million compared to a strategy of collecting information about both immedi-
ately. ConClusions: We demonstrate that when parameters vary across cohorts, 
the optimal information collection policy, for both time-varying and static param-
eters, may be to delay information collection until it is more likely to influence 
the decision. Our dynamic programming framework enables the consideration of 
delayed information collection in numerous contexts.
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objeCtives: There are few economic evaluations of strategies for screening, 
diagnosing, and treating autism spectrum disorder (ASD). The objective of this 
study was to create a discrete event simulation (DES) model of the pathway of 
care for children with suspected ASD up to age 6. This model will be used to 
perform economic evaluations of screening protocols, diagnostic tests and treat-
ments for ASD. Methods: A DES model was conceived to simulate a Canadian 
population of children with suspected ASD. Attributes important for simulation 
of entities were identified from the literature and expert opinion. Important 
categories of attributes included ASD risk factors, ASD co-morbidities, meas-
ures of development, and measures of severity of ASD. The pathway of care 
was created with review of current practice guidelines as well as consultation 
with developmental pediatricians. Queuing for screening, diagnosis, and treat-
ment comes from entities accessing limited resources over a period of time. 
We will use calibration techniques to set resource and time limits to match 
the wait times reported in the literature. Results: A DES model was built for 
children with suspected ASD up to age 6. The DES model addresses population 
heterogeneity by including risk factors such as gender, autistic siblings, and older 
parents, genetic co-morbidities, and physical and psychological co-morbidities. 
The DES model simulates outcomes in terms of ASD severity, IQ, and language 
skills. The DES model addresses the issues of wait times that are relevant in 
ASD screening, diagnosis, and treatment by having entities queue for limited 
resources. ConClusions: The DES modelling approach is well-suited to model-
ling the pathway of care for ASD patients. Patients with ASD have a wide variety 
of disabilities and co-morbidities that can be captured in DES modelling. DES 
modelling is also able to address issues of wait times that are prevalent in ASD 
screening, diagnosis, and treatment.
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objeCtives: Congestive heart failure (CHF) is a major health burden with an 
increasing prevalence and incidence. Risk factors associated with recurrent CHF 
following surgical AVR has been previously described in a multivariate model by 
Ruel et al. The objective of this study was to re-create the previously described 
model without relying on the initial patient-level data. Methods: The semipara-
metric Cox proportional hazards models described by Ruel et al. was based upon 
1563 patients who underwent AVR at the University of Ottawa Heart Institute 
between 1976 and 2001. Adjusted hazard ratios and mean covariate values were 
reported. Several distributions, including exponential, Weibull, and competing-
risks, were tested to determine, which would better reproduce the recurrent CHF 
function. Results: All candidate models successfully reproduced the published 
results by Ruel et al. One model was converted into a customizable excel model. 
Clinically relevant variables included in the re-created model included valve size, 
mean transprosthesis gradients, patient age, atrial fibrillation, preoperative NYHA 
class, body surface area, coronary artery disease, and smoking. After adjustment 
of patient and valve characteristics, the model predicted freedom from recur-
rent HF in the Ruel Cohort at 1, 5, 10, and 15 years as 98.4%, 90.8%, 73.2%, and 
43.5% compared with published values of 98.6%, 88.6%, 73.9%, and 45.2%, respec-
tively. ConClusions: The re-created model accurately predicted CHF recurrence. 
Statistical models validated using large patient cohorts can be useful in population 
management.
